ICH E6(R3): Inside the Biggest GCP Overhaul in 25 Years, and What It Means for Clinical Trial Sites
Seven Health's guide to ICH E6(R3), the most significant Good Clinical Practice overhaul in a generation, and what it means for site quality systems.
With over 20 years of distinguished commercial experience spanning clinical research business development, pharmaceutical sales, medical devices. He has built a reputation for accelerating clinical timelines architecting high-performing partnerships
37 posts
Author since 2025
Asia-Pacific's Rise as a Global Clinical Trial Hub: What It Means for U.S. Site Networks
How Asia-Pacific's rapidly growing clinical trials market is reshaping the competitive bar for U.S. clinical trial site networks in 2026.
AI-Driven Protocol Design and Risk-Based Monitoring: Inside Clinical Research's Next Technology Wave
Seven Health breaks down clinical research's next AI wave: protocol design automation and risk-based monitoring, and what it means for sites.
Clinical Trials Market Outlook: Growth Trends, CRO Consolidation, and What's Next
The clinical trials industry is undergoing structural changes that will define competitive positioning for sponsors, CROs, and research sites over...
Real-World Evidence: How RWE Is Reshaping Clinical Trial Design
How real-world evidence has moved from a post-approval afterthought to a central input in clinical trial design and regulatory strategy.
Oncology and Rare Disease Trials: Why Rising Complexity Is Reshaping Site Selection
A Seven Health look at why oncology and rare disease complexity is reshaping what sponsors look for in a clinical trial site partner.
Navigating CRO-Sponsor-Site Relationships: A Business Development Guide
Understanding the three-way relationship between sponsors, CROs, and sites, and how to build a business development strategy that works across all of them.